Ergomed Share Discussion Threads

[battlebus2] 31/5/2016 11:42

Thanks Rivaldo, hope your wrong, bit of a bounce back this morning.

[rivaldo] 19/5/2016 11:43

Hi bb2 - you'd better read my post 38 again as I'm not interested here any more!

I think this acquisition is a terrible idea. Happy to be persuaded otherwise, but at first look it destroys the entire rationale for investing in this company.

[battlebus2] 19/5/2016 10:56

Well this is a terrible start, new lows.....pathetic timing...

[battlebus2] 13/5/2016 08:40

Moving well this morning, 140 hopefully a distant memory :))

[battlebus2] 12/5/2016 13:32

Good to see your interested Rivaldo, I've added a few to the portfolio, looks good value imv and should head back to the 170 level.

[proactivest] 06/5/2016 13:00

Video interview with Andrew Mackie



Andrew Mackie, chief business officer of Ergomed Plc (LON: ERGO), says the company is looking for more acquisitions principally specialist service companies operating in the post-marketing arena.

The pharma services specialist has just bought Haemostatix and its pipeline of topical products to treat surgical bleeding. Mackie is confident the products could get to market quickly and economically, but tells investors there are earlier monetisation moments in terms of deals with licencing partners.

Concurrent with this week’s acquisition, Ergomed raised £9 million to assist the development of Haemostatix products and fund bolt on acquisitions to cover geographical holes globally and enhance service delivery.

[rivaldo] 04/5/2016 13:45

Not a holder here, but been watching for a long time puzzled by the share price fall, and now I know the reason.

The placing at 140p is fair enough, but imo the entire attraction of this company has been destroyed by today's transaction. I liked the combination of a reasonably low P/E combined with little downside and large upside from the investments in higher-risk drugs via the investment of costs.

Today's acquisition commits ERGO to long-term development with no commercialisation until 2020 at the earliest. The "intention for Ergomed to remain profitable at the EBITDA level" is just a sop.

The entire rationale for investing has been completely changed. Why couldn't they just continue to do what they were doing?

ERGO is uninvestable for me now. It will likely come off my watchlist unless someone/something changes my mind.

[proactivest] 12/4/2016 15:21

Video interview with Stephen Stamp



Ergomed (LON:ERGO) Chief Financial Officer Stephen Stamp tells Proactive Investors about plans to make bolt-on acquisitions in 2016. "My background is in investment banking, capital raising, that is the kind of CFO background I have so that is what I hope to bring to the party and in coming quarters you can expect to see an announcement or two" he says.

Phillips says Deltex has a small pipeline they are looking at and is keen to broaden the firm's geographical reach. "We feel we are a little under-represented in the U.S. - that is one place we are looking and there a few spots in Europe where we have some gaps we would like to fill in... and then to the Far East, but not China" he says. "China is a special market and there are other places for us to go first".

[mfhmfh] 12/4/2016 08:22

I also agree - great results with zero debt and looking to make acquisitions. Holding for now but will add on upward movement. Wonder if Mark Slater will increase his holding? IMHO.

[jimmywt] 12/4/2016 08:14

Very happy with the results. I have only held a fairly small holding here but will look to increase my position significantly after this reassuring update.

[03jojones] 02/2/2016 09:37

New link to an interview with new CFO Stephen Stamp

[mfhmfh] 26/11/2015 18:50

small breakout few days ago, hopefully just a healthy retrace before further upward movement

[18bt] 29/9/2015 13:05

Looks a bit churlish response to a cracking set of results

[aim_trader] 10/9/2015 14:33

Ergomed CFO Neil Clark will be presenting to investors at the Chesterfield Hotel in Mayfair on the 17th September. To register to attend this event please click here:

[little minx] 23/7/2015 19:14

Yes but slater investments obviously see something there and with this new dementia drug trial going well pharma is back in fashion - so to speak.I have a few VRP and APH - the latter slater also holds. Kept looking at gwp and did nothing and now seriously regretting.I am sure the guy from Shire has a clear motive for both parts of the business.Results this year will be interesting. Perhaps one of the trials is doing very well. Only time will tell.

[hydrus] 23/7/2015 18:59

Does anyone know anymore regarding Devbods point - how much they paid for the acquisition? Who owned the company they bought? I recall at IPO they used the money raised to buy a company the Ergo Directors owned, so there was already a bit of a question mark about that transaction.

[hydrus] 23/7/2015 18:55

Of course the Board do sound good. Hmm tricky one this - originally I quite liked the model but having thought about it more I can't help but thinking what a great little business the clinical trials but would be on its own. Anyway I plan to keep watching and see how it all unfurls.

[hydrus] 23/7/2015 18:39

If ERGO just focussed on clinical trial support etc it would be a really interesting and profitable, growing company which the market would fully understand. What I don't get is why management then gamble a wedge of the profits on drugs going through trials, many of which I assume will fail. If I wanted to invest in a company with some potential blockbuster drugs I could pick one of many blue sky, zero profit companies on the stock market myself. I am not saying it's a poor company by any means but just feel it could be a better investment if it was simpler.

[little minx] 23/7/2015 15:46

Thanks Buff. I did read a little about them at the beginning of this thread and noticed that the main man was originally at Shire - which bodes very well for the company and his knowledge of the industry.

I know somebody who used to work for a company that managed clinical trials and I know from what she used to say that it is a big business.

I have taken a small holding today. Will probably increase it over the next few weeks.

Off the top of your head, when is the next trading update roughly due?

[buffetteer] 23/7/2015 15:40

Minx
2 sides of the business -one doing clinical trials and pharma records for pharma companies .both growing very well - 15& 30% respectively .This market for out-sourced services is growing .
The other part is the co-development of 5 drugs that Ergo have given clinical trial discounts to in order to share in the upside .Arguably there is no value in the share price of these phase 2 & 3 trials .This has cost the company over £2m in reduced profitability but the opportunity is tens of millions .The first is due end of year I think .
Personally if were you I would read the strategy note in the annual accounts which gives a lot of detail in what this exciting company is doing .It is backed up by a first class non -exec Chairman and 2 other non-execs -all of whom are very highly rated and experienced operators who would not have joined this small company for the fun of it .

[little minx] 23/7/2015 14:31

Slater has just taken a holding in this company. It sounded pretty interesting to me and looks like growth for this year will be good.

[little minx] 23/7/2015 09:45

This looks an interesting company and as pharma is so much in the spotlight again was wondering if anybody could give a brief outline of recent events.